Building a Resilient Supply Chain: Lessons from the Pandemic
The COVID-19 pandemic revealed the fragility of global supply chains, particularly for essential goods like medicines. For the pharmaceutical industry, the dependence on a single source for many Active Pharmaceutical Ingredients (APIs) and raw materials created a major risk. In response, countries around the world have been focused on building more resilient, regional supply chains. India, with its robust manufacturing infrastructure, has become a central part of this strategy. By encouraging domestic production of critical APIs through government incentives and private-sector investment, India is not only strengthening its own pharmaceutical security but also providing a more reliable alternative for global partners. The lessons learned from the pandemic have reinforced the strategic importance of a strong domestic API industry and have led to a renewed push for self-reliance. This is a key theme driving the current and future direction of the INDIA API Market.